Adverse drug reactions of ranélate de strontium (Protelos®) in France;Ranélate de strontium (Protelos®): effets indésirables rapportés en France

Presse Medicale

Volumn 40, Issue 10, 2011, Pages

  Jonville Bera, Annie Pierre ^a   Autret Leca, Elisabeth ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STRONTIUM RANELATE;

ADVERSE DRUG REACTION; AMNESIA; ARTICLE; CARDIOVASCULAR DISEASE; CONFUSION; CONVULSION; DIGESTIVE SYSTEM DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRESSLER SYNDROME; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG UTILIZATION; ERYTHROBLASTOPENIA; FRANCE; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; NEUROLOGIC DISEASE; PANCREATITIS; PANCYTOPENIA; RISK FACTOR; SKIN DISEASE; THROMBOCYTOPENIC PURPURA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; THIOPHENES;

EID: 80053176839     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.07.010     Document Type: Article

References (34)

1. Kardaun S.H., Sidoroff A., Valeyrie-Allanore L., Halevy S., Davidovici B.B., Mockenhaupt M., et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?. Br J Dermatol 2007, 156:609-611.
2. Bégaud B., Evreux J.C., Jouglard J., Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985, 40:111-118.
3. Hazell L., Shakir S.A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396.
4. Halil M., Cankurtaran M., Yavuz B.B., Ulger Z., Piskinpasa S., Gedik A., et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007, 41:41-45.
5. Bayhan I., Uygur D., Ugurlu N., Ozaksit G. Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women. Rheumatol Int 2009, 29:263-266.
6. Quere I., Chasse J.F., Janbon C. Homocystéine et maladie thromboembolique veineuse: une nouvelle approche du risque thrombotique veineux. Sang Thromb Vaiss 1997, 9:339-345.
7. Ulger Z, Guret EI, Halil M, Oozen G, Kalan I, Seringec N, et al. Hemorheological changes with strontium ranelate treatment do not seem to be related to its claimed prothrombotic effects. Arch Gerontol Geriatr 2010 Dec 15 [Epub ahead of print].
8. Breart G., Cooper C., Meyer O., Speirs C., Deltour N., Reginster J.Y. Osteoporosis and venous thromboembolisme: a retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010, 21:1181-1187.
9. Osborne V., Layton D., Perrio M., Wilton L., Shakir S.A.W. Incidence of venous thromboembolism in users of stontioum ranelate. An analysis of data from e prescription-event monitoring study in England. Drug Saf 2010, 33:579-591.
10. Lamberg A.L., Horvath-Puho E., Christensen S., Sorensen H.T. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study. Osteoporos Int 2010, 21:1191-1197.
11. Jonville-Béra A.P., Crickx B., Aaron L., Hartingh I., Autret-Leca E. Strontium ranelate-induced DRESS syndrome: first two case reports. Allergy 2009, 64:658-659.
12. Iyer D., Buggy Y., O'Reilly K., Searle M. Strontium ranelate as a cause of acute renal failure and dress syndrome. Nephrology 2009, 14:624.
13. Kramkimel N., Sibon C., Le Beller C., Saiag P., Mahé E. Bullous DRESS in a patient on strontium ranelate. Clin Exp Dermatol 2009, 34:e349-e350.
14. Musette P., Brandi M.L., Cacoub P., Kaufman J.M., Rizzoli R., Reginster J.Y. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010, 21:723-732.
15. Lens S., Crespo G., Carrion J.A., Miquel R., Navasa M. Severe acute hepatitis in the dress syndrome: report of two cases. Ann Hepatol 2010, 9:198-201.
16. Paz Y.M., Rodriguez C.J. Rash and renal failure secondary to strontium ranelate. Med Clin 2010, 134:85-86.
17. Eshki M., Allanore L., Musette P., Mipied b, Grange A., Guillaume J.C., et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2009, 145:67-72.
18. Tennis P., Stern R.S. Risk of serious cutaneous disorders after initiation of use of phenytoine, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997, 49:542-546.
19. Cacoub P., Musette P., Descamps V., Meyer O., Speirs C., Finzi L., et al. The DRESS Syndrome: a literature review. Am J Med 2011, 124:588-597.
20. Kinyo A., Belso N., Nagy N., Palvölgyi A., Nagy I., Korom I., et al. Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis. Acta Derm Venereol 2001, 91:205-206.
21. Carracedo-Martínez E., Pía-Morandeira A. Impact of a health safety warning on strontium ranelate utilization. Gac Sanit 2010, 24:151-153.
22. Sainz M., del Pozo J.G., Arias L.H., Carvajal A. Strontium ranelate may cause alopecia. BMJ 2009, 338:b1494.
23. Lee H.Y., Lie D., Lim K.S., Thirumoorthy T., Pang S.M. Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis. Osteoporos Int 2009, 20:161-162.
24. Smith E.V., Shipley D.R. Severe exfoliative dermatitis caused by strontium ranelate: two cases of a new drug reaction. Age Ageing 2010, 39:401-403.
25. Boada A., Carrascosa J.M., Leal L., Ferrándiz C. Generalized cutaneous drug eruption due to strontium ranelate. J Eur Acad Dermatol Venereol 2009, 23:321-322.
26. Cortet B. Osteoporosis: from early fracture prevention to better bone health with strontium ranelate. Rheumatology 2009, 48:iv14-iv19.
27. El-Hajj Fuleihan G. Strontium ranelate-a novel therapy for osteoporosis or a permutation of the same?. N Engl J Med 2004, 350:504-506.
28. Reginster J.Y., Bruyère O., Sawicki A., Roces-Varela A., Fardellone P., Roberts A., et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8years. Bone 2009, 45:1059-1064.
29. Ringe J.D., Doherty J.G. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int 2010, 30:863-869.
30. Seeman E., Boonen S., Borgström F., Vellas B., Aquino J.P., Semler J., et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80years of age. Bone 2010, 46:1038-1042.
31. Grosso A., Douglas I., Hingorani A., MacAllister R., Smeeth L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008, 66:689-694.
32. Inderjeeth C.A., Foo A.C.H., Lai M.M.Y., Glendenning P. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009, 44:744-751.
33. Briot K., Tremolliere F., Thomas T., Roux C. Quelle est la durée optimale des traitements dans l'ostéoporose postménopausique ?. Rev Rhum 2007, 74:27-34.
34. Park-Wyllie L.Y., Mamdani M.M., Juurlind D.N., Hawker G.A., Gunraj N., Autin P.C., et al. Bisphosphonate use and the risk of subtrachanteric or femora shaft fractures in older women. JAMA 2011, 305:783-789.